Compugen at Stifel 2025: AI-Driven Immuno-Oncology Insights

Compugen Ltd. (CGEN) presented at the Stifel 2025 Healthcare Conference, outlining its AI-driven immuno-oncology pipeline and robust financial position. The company is advancing its COM-701 (PVRIG inhibitor) in a platinum-sensitive ovarian cancer trial, with interim results anticipated in Q1 2027, and its GSO-321 (IL-18BP inhibitor) in Phase 1 with Gilead, which has already generated $90 million and offers potential for up to $758 million in additional milestones plus low double-digit royalties. Furthermore, Compugen's partnership with AstraZeneca for the TIGIT bispecific volrustomig has yielded $30 million, with a potential $170 million more and mid-single digit royalties on estimated $5 billion sales, positioning the company to benefit from potential TIGIT market revalidation. Compugen projects a cash runway until Q3 2027, providing stability for its ongoing clinical programs and computational target discovery efforts.

Analysis

Compugen Ltd. (CGEN) presented a moderately positive outlook at the Stifel 2025 Healthcare Conference, emphasizing its AI-driven immuno-oncology platform and robust financial position. Strategic partnerships with AstraZeneca (AZN) for volrustomig and Gilead (GILD) for GSO-321 have already generated $120 million in milestones, with potential for an additional $928 million and significant tiered royalties, underpinning a projected cash runway until Q3 2027 without further income. This financial stability supports ongoing clinical development and internal pipeline expansion.
The company's lead asset, COM-701 (PVRIG inhibitor), is progressing in a platinum-sensitive ovarian cancer trial, with interim results expected in Q1 2027. Its Fc-reduced design is highlighted as a key differentiator from discontinued competitors, aiming to avoid T-cell depletion. The GSO-321 (IL-18BP inhibitor) program, licensed to Gilead, is in Phase 1, representing a novel approach to cytokine biology with potential for significant future milestones.
Despite a paused internal TIGIT program (COM-902) due to market disputes, Compugen stands to benefit from a potential revalidation of the TIGIT class through AZN's volrustomig, an Fc-reduced bispecific showing promising long-term data in lung and bladder cancer. Upcoming ARCUS data in 2026 and AZN's 11 Phase 3 trials are critical catalysts that could resolve the TIGIT debate and unlock substantial royalty streams for CGEN. The company's validated computational platform continues to generate new, first-in-class assets, mitigating competitive pressures.

Key Decisions for Investors

• Monitor the Q1 2027 interim results for COM-701 in ovarian cancer for clinical significance and potential accelerated approval pathways.
• Evaluate the impact of upcoming TIGIT data, particularly ARCUS in 2026 and AstraZeneca's Phase 3 readouts, on Compugen's volrustomig royalty potential and the broader TIGIT market revalidation.
• Assess the company's sustained cash runway until Q3 2027 and its ability to leverage non-dilutive partnership funding and its AI-driven platform for continued pipeline expansion and value creation.